Cornelis Blauwendraat, Huw R Morris, Kendall Van Keuren-Jensen, Alastair J Noyce, Andrew B Singleton
{"title":"The temporal order of genetic, environmental, and pathological risk factors in Parkinson's disease: paving the way to prevention","authors":"Cornelis Blauwendraat, Huw R Morris, Kendall Van Keuren-Jensen, Alastair J Noyce, Andrew B Singleton","doi":"10.1016/s1474-4422(25)00271-6","DOIUrl":null,"url":null,"abstract":"Genetics research in Parkinson's disease has identified over 100 risk loci, yet translating these findings into understanding of disease mechanisms, clinical and pathological heterogeneity, and disease progression remains a challenge. This task requires exploring how genetic risk factors operate over time, interact with environmental factors, and contribute to the diverse ways in which disease manifests. The development of α-synuclein seeding amplification assays (SAAs) offers the opportunity to understand Parkinson's disease pathogenesis and heterogeneity, and drive the development of new disease-modifying and prevention interventions. Emerging biomarker tools, such as α-synuclein SAAs, hold great promise in uncovering the pathological underpinnings of Parkinson's disease and related disorders. Integrating α-synuclein SAAs with genetic data will redefine Parkinson's disease biology and, importantly, identify the temporal sequence of genetic risk, whether that be as a driver of an initiating pathological event or as a response to an initiating stochastic, environmental, or other genetic event. Furthermore, studying genetic and environmental influences in individuals who are asymptomatic but have detectable α-synuclein pathology will provide actionable insights for disease prevention and therapeutic interventions.","PeriodicalId":22676,"journal":{"name":"The Lancet Neurology","volume":"68 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1474-4422(25)00271-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Genetics research in Parkinson's disease has identified over 100 risk loci, yet translating these findings into understanding of disease mechanisms, clinical and pathological heterogeneity, and disease progression remains a challenge. This task requires exploring how genetic risk factors operate over time, interact with environmental factors, and contribute to the diverse ways in which disease manifests. The development of α-synuclein seeding amplification assays (SAAs) offers the opportunity to understand Parkinson's disease pathogenesis and heterogeneity, and drive the development of new disease-modifying and prevention interventions. Emerging biomarker tools, such as α-synuclein SAAs, hold great promise in uncovering the pathological underpinnings of Parkinson's disease and related disorders. Integrating α-synuclein SAAs with genetic data will redefine Parkinson's disease biology and, importantly, identify the temporal sequence of genetic risk, whether that be as a driver of an initiating pathological event or as a response to an initiating stochastic, environmental, or other genetic event. Furthermore, studying genetic and environmental influences in individuals who are asymptomatic but have detectable α-synuclein pathology will provide actionable insights for disease prevention and therapeutic interventions.